Actinium Pharmaceuticals, Inc.ATNM
Price (close)
$1.20
Market cap
$37.7M
P/E
3.3x
Revenue (TTM)
$90,000
Net income
$11.3M
Dividend yield
—
1-year total return
-24.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Actinium Pharmaceuticals, Inc. does.
of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach
to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies.
Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.1M | $1.0M | $81,000 | — | $90,000 |
| Net income | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M |
| Free cash flow | -$21.9M | -$21.0M | $8.3M | -$47.5M | -$33.1M | -$24.7M |
More on ATNM.
- Actinium Pharmaceuticals, Inc. summary
- Actinium Pharmaceuticals, Inc. financial statements
- Actinium Pharmaceuticals, Inc. key metrics
- Actinium Pharmaceuticals, Inc. health scores and style box
- Actinium Pharmaceuticals, Inc. earnings
- Actinium Pharmaceuticals, Inc. dividends
- Actinium Pharmaceuticals, Inc. valuation
- Actinium Pharmaceuticals, Inc. ownership and insiders
- Actinium Pharmaceuticals, Inc. peers
Figures from Actinium Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.